StonvexLoading…
StonvexStonvexStonvexCore line items from CDNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $379.81M | $333.79M | $280.32M | $321.79M |
Operating Income | $-30.78M | $40.77M | $-203.36M | $-77.23M |
Net Income | $-21.35M | $52.55M | $-190.28M | $-76.61M |
EPS (Diluted) | $-0.40 | $0.93 | $-3.54 | $-1.44 |
Total Assets | $413.23M | $491.05M | $466.83M | $542.99M |
Total Liabilities | $110.13M | $112.62M | $205.50M | $112.08M |
Cash & Equivalents | $65.43M | $114.69M | $82.20M | $89.92M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 50.92M | 54.77M | 51.50M | 53.53M |